New Discoveries and Future Trend for Prostate Cancer Research and Treatment

Dear Colleagues,

Globally, about 1,276,106 new cases of prostate cancer were recorded in 2018. In the United States, it is the most commonly diagnosed cancer in elderly men, with more than 191,930 cases that will be diagnosed and 33,330 estimated deaths in 2020. The development of castration-resistant PCa (CRPC) is a current major concern in PCa management, where most patients develop aggressive forms of tumors. The first option for treating CRPC patients is to use anti-androgen therapies such as Enzalutamide and Abiraterone. The development of aggressive and metastatic CRPC (mCRPC) suggests that there is an urgent need to promote studies that aim to understand the molecular mechanisms underlying these changes in tumor cells and their microenvironment and develop novel strategies for treating and improving the overall survival of prostate cancer patients.

In this Special Issue, we will cover the following research topics:

1. the biological significance of key molecules that contribute to prostate cancer progression and metastasis and novel approaches to their molecular targeting;
2. the role of the tumor microenvironment (tumor–stromal interaction) in promoting prostate cancer progression and recurrence;
3. the discovery of novel and reliable prostate cancer biomarkers (diagnostic and prognostic);
4. updates on therapeutic approaches, clinical trials, and FDA-approved drugs for the treatment of prostate cancer; and
5. prostate cancer prevention and community awareness.

Prof. Dr. Zakaria Y. Abd Elmageed
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.